US Patent

US11806428 — Intranasal pharmaceutical dosage forms comprising naloxone

Formulation · Assigned to Harm Reduction Therapeutics Inc · Expires 2032-05-11 · 6y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an intranasal dosage form of naloxone that contains at least 0.5 mg of naloxone HCl in a volume of 250 microliters or less.

USPTO Abstract

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11806428
Jurisdiction
US
Classification
Formulation
Expires
2032-05-11
Drug substance claim
No
Drug product claim
Yes
Assignee
Harm Reduction Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.